Rochelle Lazarus - Merck Independent Director
| MRK Stock | MXN 2,176 56.07 2.65% |
Director
Ms. Rochelle B. Lazarus is Independent Director of the Company since 2004.
| Age | 70 |
| Tenure | 20 years |
| Phone | 908 740 4000 |
| Web | https://www.merck.com |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Patricia Tracey | United States Steel | 67 | |
| Daniel Quintanilla | GMxico Transportes SAB | 43 | |
| Glenda McNeal | United States Steel | 55 | |
| Eugene Sperling | United States Steel | 60 | |
| Murry Gerber | United States Steel | 66 | |
| Rodney Slater | Verizon Communications | 62 | |
| Jeffrey Raikes | Costco Wholesale | 59 | |
| Han Kim | Samsung Electronics Co | 67 | |
| Eun Kim | Samsung Electronics Co | 57 | |
| Gregory Wasson | Verizon Communications | 58 | |
| Xun Chen | Applied Materials | 47 | |
| Yvonne McGill | Applied Materials | N/A | |
| Aart Geus | Applied Materials | 63 | |
| Stephen Forrest | Applied Materials | 66 | |
| Adrianna Ma | Applied Materials | 43 | |
| Dennis Powell | Applied Materials | 69 | |
| Dan Dinges | United States Steel | 65 | |
| Arturo Ayub | GMxico Transportes SAB | 51 | |
| Melanie Healey | Verizon Communications | 56 | |
| Richard Galanti | Costco Wholesale | 67 | |
| Gregory Weaver | Verizon Communications | 65 | |
Management Performance
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Independent Director | ||
| Craig Thompson, Independent Director | ||
| Cristal Downing, Ex Officer | ||
| Jennifer Zachary, General Counsel | ||
| Rochelle Lazarus, Independent Director | ||
| Michael Rosenblatt, Executive Vice President Chief Medical Officer | ||
| Wendell Weeks, Independent Director | ||
| Michael Holston, Executive Vice President Chief Ethics and Compliance Officer | ||
| Paul Rothman, Director | ||
| Mary Coe, Director | ||
| Adele Ambrose, Senior Vice President Chief Communications Officer | ||
| Caroline Litchfield, Ex CFO | ||
| Joseph Romanelli, IR Contact Officer | ||
| Mirian GraddickWeir, Executive Vice President - Human Resources | ||
| Peter Wendell, Independent Director | ||
| John Noseworthy, Independent Director | ||
| Jennifer Mauer, VP Communications | ||
| Leslie Brun, Independent Director | ||
| Julie Gerberding, Executive Vice President - Strategic Communications, Global Public Policy & Population Health | ||
| Inge Thulin, Director | ||
| Pamela Craig, Director | ||
| Patricia Russo, Independent Director | ||
| David Williams, Ex Officer | ||
| Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division | ||
| Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller | ||
| Lisa LeCointeCephas, VP Officer | ||
| Robert Davis, CFO and Executive VP | ||
| Robert Kidder, Independent Director | ||
| Thomas Cech, Independent Director | ||
| Michael Nally, Chief Marketing Officer | ||
| Peter Dannenbaum, VP Relations | ||
| Clark Golestani, Executive Vice President CIO | ||
| William Harrison, Lead Independent Director | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer | ||
| Steven Mizell, Chief Human Resource Officer | ||
| Jim Scholefield, Chief Information and Digital Officer | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Adam Schechter, President of Global Human Health and Executive VP | ||
| Carlos Represas, Independent Director | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman, CEO and Pres | ||
| Frank Clyburn, Chief Commercial Officer | ||
| Robert JD, Pres Chairman |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.24 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 5.9 T | |||
| Shares Outstanding | 2.54 B | |||
| Shares Owned By Insiders | 0.10 % | |||
| Shares Owned By Institutions | 76.37 % | |||
| Price To Earning | 469.71 X | |||
| Price To Book | 6.28 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |